Cite
MLA Citation
David M Gershenson et al.. “Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.” Lancet, vol. 399, no. 10324, 2022, pp. 541–553. http://access.bl.uk/ark:/81055/vdc_100150528050.0x000047